SUMMARY A retrospective cohort study of hypertensive employees to evaluate the impact of worksite antihypertensive treatment (WST) on cardiovascular disease (CVD) over S'/i years is reported. In a union-sponsored screening from August 1973 to February 1974 hypertensives (S= 160 and/or 95 mm Hg, or on medication) were identified. Of these, standardized criteria were met by 344, of whom 150 chose WST and 194 referred care (RC). The study groups were similar in age and sex composition. Union hospitalization and death records through 1982 revealed that CVD rates were fewer in WST than RC (3.0 vs 5.4/100 person-years; p < 0.01). By contrast, nonCVD rates were similar (8.1 vs 9.6). All-cause mortality rate in WST (0.89) was significantly (p < 0.05) lower than that in RC (1.81), as was the standard mortality ratio (55.1), based on U.S. mortality in 1978. CVD mortality was also lower (0.48 vs 1.10; NS). Persons with an initial blood pressure (BP) < 160/95 mm Hg had CVD event rates that were low and similar in WST and RC (3.6 vs 3.5). However, among those with elevated BP at entry, WST subjects fared significantly better than RC (2.8 vs 6.1; p < 0.001). Furthermore, in WST, previously treated patients with elevated BP at screening experienced one-third the CVD morbidity of their counterparts in RC (3.1 vs 10.8; p < 0.01). These results extend previous evidence that WST is an effective method to achieve BP control and demonstrate that this approach to the management of hypertension alters health outcomes favorably and significantly. had demonstrated that blood pressure (BP) control reduced the incidence of cardiovascular disease (CVD). '~3 At the same time, it was apparent that, despite availability of effective antihypertensive therapy, large numbers of identified and treated hypertensives were not achieving BP control. 4 " 7 In an attempt to overcome this deficiency, several modifications of conventional approaches to the management of hypertension evolved. Among these, programs to provide worksite-based antihypertension treatment attained widespread acceptance. Early studies demonstrated that systematic, protocol-directed care provided at the worksite, primarily under the aegis of a nurse, was safe, acceptable, and achieved a high degree of BP control.
B
Y the late 1960s prospective controlled trials had demonstrated that blood pressure (BP) control reduced the incidence of cardiovascular disease (CVD). '~3 At the same time, it was apparent that, despite availability of effective antihypertensive therapy, large numbers of identified and treated hypertensives were not achieving BP control. 4 " 7 In an attempt to overcome this deficiency, several modifications of conventional approaches to the management of hypertension evolved. Among these, programs to provide worksite-based antihypertension treatment attained widespread acceptance. Early studies demonstrated that systematic, protocol-directed care provided at the worksite, primarily under the aegis of a nurse, was safe, acceptable, and achieved a high degree of BP control. 8 -9 Subsequent studies demonstrated that such systematic approaches to care were actually more effective than those conventionally available in the community. 10 " The assumption that better BP control would be matched by greater reduction in CVD events has encouraged expansion of these and similar programs. However, recent findings indicate that greater BP control is not invariably associated with better health outcomes. 12 Therefore, it is of more than academic interest to evaluate the effectiveness of worksite antihypertensive therapy in terms of its impact on CVD morbidity and mortality.
To this end, we have applied the method of a retrospective cohort study to compare, over an 8'/2-year period, the morbidity and mortality of hypertensive storeworkers who joined a worksite treatment (WST) program with that of a comparable group that was referred to community care (RC).
Material and Methods
Hypertensive patients included in this study were identified through screenings of United Storeworkers Union members at two large department stores in New York City between May 1973 and February 1974 in the initial phase of a previously described union-sponsored worksite-based hypertension control program." g The data sources for the study were: 1) information obtained at screenings stored on magnetic tape maintained by the Hypertension Control Program; and 2) records of employment, hospitalization, and death for each member, maintained by the central union office.
Of 2303 employees screened, 604 had elevated BP O 160/95 mm Hg) at initial testing or were taking hypqtensive medication. As shown in figure 1, of these, 210 elected WST and the remaining 394 formed the RC group. RC was reduced to 361 by the exclusion of 33 who joined WST later than 1973-74. These employees were then reviewed according to rigid criteria to select study groups that would be free of bias in selection, data collection, and analysis." M The final study subjects (150 WST and 194 RC) had union records available and met at least one of the following criteria: 1) elevated BP levels (^ 160/95) at initial and one follow-up visit; 2) initial BP levels 3= 200 systolic and/or > 110 diastolic; and 3) on hypotensive therapy at screening. Excluded were 60 WST and 167 RC because either they did not meet the above criteria or their union records were not traceable.
The design is that of a retrospective observational cohort study covering a period of 8'/2 years from January 1974 through June 1982. Union records permitted complete follow-up of these two groups for hospitalizations and deaths. Interruptions in follow-up occurred only due to death (39) or termination of union membership (4) . Retirement of a union employee did not affect follow-up since he or she continued to enjoy union benefits.
Union records on hospitalizations included date of admission and discharge, diagnosis at discharge, as well as hospital name. The diagnosis at discharge and the cause of death obtained from hospital reports and death certificates were classified under eight major conditions:
Hypertension

Myocardial infarction
Other coronary ischemia Cerebrovascular accident and transient ischemic attacks Congestive heart failure, peripheral vascular disease, and renal disease Venous disease unrelated to hypertension (hemorrhoids, thrombophlebitis) Diabetes Noncardiovascular events, including accidents and injuries.
The first five were grouped as CVD and the remaining three as nonCVD. Death of union members was also recorded to validate payment of death benefits, but information on cause of death (generally derived from the death certificate) was not available for five cases, of which three were obtained by telephone and two remain unknown. In addition to these data from union records, demographic information, previous clinical and BP treatment history, smoking history, and initial BP levels were available from hypertension program screening data. The impact of the WST program on CVD morbidity and mortality was evaluated by comparing aggregate rates of hospitalization and death expressed as per 100 person-years of follow-up for WST and RC groups. Significance of differences in rates was assessed by the z score. Standardized mortality ratios (SMR) were calculated by taking the ratio of total observed numbers to total expected numbers of death (X 100). Expected numbers of deaths were computed by multiplying U.S. age-specific death rates for 1978 (midyear for 1973-82) by the corresponding age distribution of person-years at risk. 
Results
The final study groups of 150 in WST and 194 in RC were comparable in sex distribution (80% female), smoking (25% and 31%), and mean age (59 years), as shown in table 1. They differed in that WST employees were more likely to be nonwhite, less likely to be taking antihypertensive medication at screening, and perhaps, as a result, to have higher BP. An unconfirmed history of heart attack was reported by three people in WST and 16 in RC. Table 2 shows the rates of hospitalization and death per 100 person-years in the two groups by type of diagnosis. There was a significant difference (p < 0.01) between WST and RC in the rate of CVD events (3.0 vs 5.4) but no difference in the rate of nonCVD events (8.1 vs 9.6). This difference in CVD rates held after excluding the 19 who reported previous history of heart attack (2.9 vs 5.1;p < 0.01). Of 38 CVD hospitalizations and deaths in WST, there were eight strokes and 13 myocardial infarctions. Of 88 CVD events in RC, there were 13 strokes and 22 myocardial infarctions.
Disaggregation of these data (table 3) demonstrates that WST patients had significantly lower CVD rates for both whites and nonwhites, females, older persons, and those in treatment at screening. The same trend was evident in males and younger people but these differences did not attain statistical significance. Surprisingly, people not previously treated had a slightly but not significantly higher rate in WST compared to RC. However, it should be noted that these patients had the lowest CVD rate of the whole group.
When outcomes were assessed according to initial BP levels (table 4), the benefit of WST treatment was confined to those with initial pressures 2s 160/95 mm Hg. Perhaps not surprisingly, those whose screening BP levels were lower had similar (and low) rates of CVD events regardless of locus of care. When the analysis was carried further to examine the experience of only those patients who entered on treatment (table  5) , not only did the WST group include significantly (p < 0.05) more patients with higher BP levels (63.8% vs 48.9%), but these patients experienced less than onethird the rate of CVD than did those with similarly elevated BPs in RC (p < 0.01). By contrast, the previously treated patients who had managed to achieve normalization of BP prior to initiation of the worksite program did not seem to achieve greater benefit by participation in WST (3.8 vs 3.5). IX. Distribution of union members according to their number of CVD hospitalizations (figure 2) shows that multiple events were more common in RC (36%) than WST (19%). As many as six to 10 hospitalizations were experienced by 6.1% of RC; there were none in this range for WST.
All-cause mortality (table 6) was significantly higher in RC than WST (p < 0.05). The mortality rate due to CVD in RC was more than double that of WST, but the difference was not significant. NonCVD mortality was similar in both groups. Of note is the fact that the average age at death for WST was 70 years and 66 for RC, although the groups had similar ages at entry. There were no deaths in the first 2 years of study in WST, but four deaths in this period in RC. Further, 45% of the deaths occurred within 6 years of follow-up in WST, whereas in RC 57% had occurred by this time. Thus, there were not only fewer deaths in the WST group, but their occurrence was delayed.
When viewed in the context of national mortality, the death rates were lower than expected in WST and more in RC (table 7) . In WST, there was a significant (p < 0.05) decrease in SMR (55.1) for all causes. For coronary heart disease (CHD), according to ICD eighth revision, an apparently similar protective effect of WST was observed, but the decrease in SMR (59.4) was not significant. This is probably due to the small number (four) of observed deaths. In RC, there was a slight excess of deaths for all causes (5.1%) and substantial, but not significant, excess for CHD (53.2%).
Discussion
The worksite has already been shown to be a setting in which a high degree of BP control can be achieved. The object of this study was to measure the impact of this treatment approach on the incidence of CVD events. The results demonstrate that union members who joined the systematic worksite treatment program sustained significantly fewer CVD events than did those who chose referral to community care. By contrast, there was no difference between the two groups in nonCVD events. CVD hospitalizations were less frequent in WST, and multiple events were fewer. Further, all cause death rate in WST was significantly lower than would have been expected according to national mortality experience. In RC, it was slightly higher. A similar trend was observed for mortality due to CVD.
Although the available data do not permit unequivocal explanation of the results noted, there are reasons to believe that the antihypertensive treatment provided by WST was responsible for the beneficial effect. First, the worksite treatment program studied here has consistently been shown to reduce the BP of over 80% of its patients, and in other studies 10 ' " BP decline in worksite programs has been shown to exceed that achieved in the community. Moreover, the observation that CVD decline occurred in the absence of change in nonCVD events lends further credence to the notion that the targeted intervention was responsible for the observed changes. The "healthy worker" ef-V-142 PR0CEED1NGS/1NTERAMERICAN SOCIETY SUPP V, HYPERTENSION VOL 5, No 6, NOV/DEC 1983 feet was apparent only among WST hypertensives, presumably because the adverse effect of their elevated BP level had been muted.
Although a prospective randomized controlled study may have been the ideal vehicle through which to test the hypothesis that WST reduced CVD events, the reality of long-term study requirements and the imperatives of the occupational setting suggested the more feasible alternative of a rigorous observational cohort study." Despite the fact that the two groups compared were self-selected, in this model the application of rigid and uniform selection criteria, such as would be applied in a prospective trial, eliminated selection bias. In addition, ascertainment of outcome events from union records was identical for members of the two groups.
Furthermore, disaggregation of the groups according to prognostically relevant subgroups permitted more refined analysis to ensure, insofar as possible, that variation in group composition did not confound the outcome. The importance of this procedure is reflected by the fact that there were certain differences in the composition of the two groups almost certainly due to self-selection. For example, there were more nonwhites and fewer employees already on treatment at the start of the study in WST. WST subjects, because of their treatment status, had significantly higher BP at screening. Although the net effect of these disparities might have biased the study against WST, when isolated subgroups were compared separately, participation in WST still was associated with fewer CVD events. In fact, disaggregation by demographic characteristics revealed lower CVD rates in WST in almost all subgroups.
Of the 19 subjects who reported a prior history of heart attack, 16 (84%) chose to remain in RC, perhaps to maintain continuity of care, which is understandable. Because it could be argued that these "sicker" patients might have been responsible for the increased CVD morbidity and mortality of RC, analysis was done excluding this group. The results were that WST subjects still had significantly better experience in terms of subsequent CVD morbidity. The strongly positive association of worksite treatment and reduced CVD occurrence, therefore, cannot be attributed to the fact that RC had a larger number of "sicker" patients.
Of particular interest were the findings when the employees were stratified according to their initial BP and treatment status. Most striking was the observation that those who entered with "controlled" BP (i.e., those who had achieved success in conventional settings) did equally well in RC and WST. There are several possible explanations for this. Perhaps such persons never really had sustained high BP and had begun prematurely on therapy. It is possible that, if their medication had been discontinued at screening, their pressure would have proved to be normal. If this were the case, they might not have been at much risk of CVD events 15 l6 and certainly could not have benefited from any treatment regardless of its locus of delivery. Another explanation may be that patients who were able to achieve BP control in conventional treatment had proved their capacity to succeed in even the most ineffective treatment regimen. For such patients, a more effective program could not improve on conventional treatment.
Conversely, those who were on treatment at screening, but nevertheless had elevated BP, did particularly well in WST. These "treatment failures" who entered WST subsequently had less than one-third the CVD events of similar employees who participated in RC. In fact, they experienced the same CVD rate as did those who were on treatment, but with controlled BP, at screening.
In terms of treatment status, those who were not treated at the initiation of the study and, therefore, by definition, had high BP (S* 160/95 mm Hg) did not achieve greater benefit by joining WST, contrary to expectations. However, the CVD rate of this untreated group was quite low by any standard and much lower than the total rate of the whole group. We can only conjecture that this hypertensive group may have included many newly identified employees whose disease had not progressed far enough to provoke complications over the period of the study. Perhaps, with a longer period of observation, the beneficial effect of WST would have appeared.
The findings of this study are important from several points of view. First, the experimental design applied here reaffirms the ability of nonexperimental, but nevertheless rigorous, methodology to address issues of medical practice that do not lend themselves to prospective controlled trials. In addition, these findings demonstrate that investment in specific health care programs can produce measurable health benefits. Moreover, in this case, the human benefit of curtailed CVD was almost certainly matched by an economic gain that more than offset the cost of the program. Finally, these data provide the needed confirmation that better BP control can, in a practical setting, be translated into improved health and extended life.
